1435TiP Adjuvant immunotherapy for resected esophageal squamous cell carcinoma with high risk of recurrence (AIRES): A multicenter, open-label, randomized, controlled phase III trial

Esophageal squamous cell carcinoma (ESCC) patients with nodal disease (ypN+) after conventional trimodality are at high risk of recurrence. Furthermore, chemoradiotherapy is not the standard of care for localized ESCC patients in many parts of the world, where neoadjuvant chemotherapy is preferred. Immunotherapy, as an adjuvant approach, has been demonstrated effective and changed the standard of care. Adjuvant immunotherapy following perioperative chemotherapy has not been investigated as a treatment option in the Asian population.